Osmotica Pharmaceuticals plc Announces Proposed Underwritten Public Offering

BRIDGEWATER, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its ordinary shares and warrants to purchase its ordinary shares. In addition, Osmotica expects to grant the underwriter of the offering a 30-day option to purchase additional ordinary shares and/or warrants to purchase ordinary shares (equal to 15% of the ordinary shares and/or 15% of the warrants offered in the public offering) at the public offering price per share and per warrant, respectively, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Read more at globenewswire.com